Literature DB >> 9187926

Diagnosis and treatment of hepatic disease in patients with HIV.

M A Poles1, E A Lew, D T Dieterich.   

Abstract

Liver involvement with opportunistic infections and neoplasms is a well-recognized component of AIDS, affecting most patients. The cause of hepatic disease in these patients may be divided into hepatitis, granulomatous disease, mass lesions, vascular lesions, hepatotoxic drugs, and nonspecific findings. With a rational approach, most patients with AIDS and liver disease can be diagnosed and treated in a cost-effective manner with low morbidity.

Entities:  

Mesh:

Year:  1997        PMID: 9187926     DOI: 10.1016/s0889-8553(05)70296-x

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  5 in total

1.  Aminotransferase profile in HIV positive patients.

Authors:  Ivan Netto; Kavindra Borgaonkar; Robert Lobo
Journal:  Indian J Sex Transm Dis AIDS       Date:  2009-07

Review 2.  Gastrointestinal manifestations of HIV infection.

Authors:  M R Wallace; O S Brann
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 3.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

4.  Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DNA assay.

Authors:  Rosamaria Tedeschi; Eliana Pivetta; Stefania Zanussi; Ettore Bidoli; Mirna Ros; Giampiero di Gennaro; Guglielmo Nasti; Paolo De Paoli
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses.

Authors:  Patricia Cornejo-Juárez; Patricia Volkow-Fernández; Luis Enrique Soto-Ramírez; Kenia Escobedo-López; Diana Vilar-Compte; Guillermo Ruiz-Palacios
Journal:  AIDS Res Ther       Date:  2006-04-06       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.